GURU.Markets stock price, segment price, and overall market index valuation
The company's share price BioLineRx Ltd.
BioLineRx is an Israeli biotech company. Its stock price reflects its transition from development to commercialization following FDA approval of its stem cell mobilization drug. The chart tells the story of this important milestone in the company's life.
Share prices of companies in the market segment - General oncology therapy
BioLineRx is an Israeli biopharmaceutical company developing drugs for the treatment of oncology and rare diseases. We have classified it in the "General Oncology" segment. The chart below shows how investors value companies with a diversified clinical development pipeline.
Broad Market Index - GURU.Markets
BioLineRx is an Israeli biotech company developing drugs for the treatment of oncology and rare diseases. As a diversified player, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with BioLineRx's performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
BLRX - Daily change in the company's share price BioLineRx Ltd.
BioLineRx Ltd.'s daily price change reflects the high volatility inherent in biotech companies. This metric measures the company's sensitivity to the commercial success of its oncology drugs and clinical trial news.
Daily change in the price of a set of shares in a market segment - General oncology therapy
BioLineRx Ltd. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with the oncology-focused BLRX helps us assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
BioLineRx is an Israeli biotech company with a broad development pipeline. Its shares react to news on numerous clinical programs. This complex, multi-factor dynamic contributes uniquely to the overall volatility of the healthcare sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization BioLineRx Ltd.
For BioLineRx Ltd., the year-over-year performance is a story of its transition to commercialization. Its market capitalization growth over the past 12 months reflects the successful approval and launch of its stem cell mobilization drug, a fundamental milestone that provides its first significant revenue stream and validates its R&D strategy.
Annual dynamics of market capitalization of the market segment - General oncology therapy
BioLineRx Ltd. is an Israeli commercial-stage biopharmaceutical company focused on oncology. Its success depends on the commercialization of its approved drug. The chart below shows how its niche strategy and portfolio expansion efforts are impacting its performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
BioLineRx, after receiving approval for its drug, has moved from the speculative biotech category to the commercial stage. Its current performance relative to the market is a test of its sales ability. Outperforming the market will indicate a successful launch and revenue growth, while lagging behind indicates difficulties with market entry.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization BioLineRx Ltd.
BioLineRx is a biopharmaceutical company with an already approved stem cell transplant drug. Its monthly performance now depends on the commercial success of this drug and news on its remaining development programs. Sales data is becoming a key driver.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
BioLineRx is a biopharmaceutical company specializing in oncology drug development. Their primary product helps mobilize stem cells for transplantation. The graph below illustrates the overall dynamics in the oncology sector, where supportive care plays an equally important role as direct treatment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of Israeli biotech companies entering the commercial stage can move on sales news. The chart below shows the overall sentiment. Is BioLineRx living up to its story, where sales growth outweighs overall market trends?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization BioLineRx Ltd.
BioLineRx, an Israeli biotech company, is sensitive to commercial and clinical news. Its weekly stock price is reflecting progress in the commercialization of its stem cell mobilization drug (Aphexda) and the release of data from its oncology programs.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
BioLineRx operates in the volatile biopharmaceutical sector, where investor sentiment often influences all players. M&A news or general regulatory changes can lift or derail the entire sector. The chart will show whether BLRX is moving with the industry or whether its drug commercialization successes are creating a different story.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
BioLineRx Ltd., as a biotech company, often ignores general market trends. Its fate depends not on GDP or inflation, but on the commercial success of its drugs and FDA decisions. The chart below clearly demonstrates how BLRX shares can live a life of their own, separate from the broader market.
Market capitalization of the company, segment and market as a whole
BLRX - Market capitalization of the company BioLineRx Ltd.
The BioLineRx chart tells the story of partnerships and drug development in Israel. This biotech's market cap reflects its strategy of licensing and developing promising drugs. Its dynamics reflect the market's valuation of its portfolio, particularly its leading stem cell mobilization drug.
BLRX - Share of the company's market capitalization BioLineRx Ltd. within the market segment - General oncology therapy
BioLineRx is an Israeli biotech company with an approved stem cell mobilization drug and other oncology developments. Its market share reflects this dual strategy. The chart shows how the market values both its commercial product and its research potential.
Market capitalization of the market segment - General oncology therapy
BioLineRx is an Israeli biotech company with a portfolio of drugs in oncology and rare diseases. The chart below shows the market capitalization of the entire oncology sector. This represents a diversified approach to cancer drug development.
Market capitalization of all companies included in a broad market index - GURU.Markets
BioLineRx is an Israeli late-stage biopharmaceutical company focused on oncology. Its market capitalization reflects the potential of its lead drug. The chart below shows the economic weight of companies close to bringing their drugs to market.
Book value capitalization of the company, segment and market as a whole
BLRX - Book value capitalization of the company BioLineRx Ltd.
BioLineRx is built on a portfolio of oncology developments. The Israeli company's book value reflects its rights to the approved stem cell mobilization drug Aphexda® and other drug candidates, as well as capital for their commercialization and R&D. The chart below shows how the company is transitioning from development to sales, strengthening its financial base.
BLRX - Share of the company's book capitalization BioLineRx Ltd. within the market segment - General oncology therapy
BioLineRx, a biopharmaceutical company, is focused on R&D. Its laboratories are its main physical asset. The S_BCap_Seg graph shows its small share of physical infrastructure, which is typical for a company in the research stage.
Market segment balance sheet capitalization - General oncology therapy
BioLineRx is a late-stage biopharmaceutical company. Its assets include intellectual property and clinical trial data. The chart shows that its balance sheet is still "light," but closer to commercialization than early-stage startups, which may require investment in production.
Book value of all companies included in the broad market index - GURU.Markets
BioLineRx's assets represent a company on the threshold of commercialization. Its book value reflects the rights to the stem cell mobilization drug APHEXDA® and the capital needed to bring it to market. This is the material base that will be transformed from research to commercial development following successful product approval.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - BioLineRx Ltd.
BioLineRx is a late-stage biopharmaceutical company. Its book value is cash. Its market capitalization primarily reflects the valuation of its lead stem cell mobilization drug, Motixafortide, and its commercial potential.
Market to book capitalization ratio in a market segment - General oncology therapy
BioLineRx is an Israeli biopharmaceutical company with a drug approved for stem cell mobilization. The chart shows how the market views the commercial success of this drug and the potential of other developments relative to its tangible assets.
Market to book capitalization ratio for the market as a whole
BioLineRx is a biopharmaceutical company with one approved stem cell mobilization drug and a pipeline of other developments. Its valuation is a combination of current revenue and future potential. The chart shows how the market values the company as it transitions from R&D to commercialization.
Debts of the company, segment and market as a whole
BLRX - Company debts BioLineRx Ltd.
BioLineRx, a biotech company, is using debt for commercialization and further research. This chart shows how the company is funding the launch of its already approved stem cell mobilization drug and conducting clinical trials of other candidates in its pipeline, such as those in oncology.
Market segment debts - General oncology therapy
BioLineRx is a late-stage Israeli biotech company with a drug approved for stem cell mobilization in cancer treatment. Commercialization of the product requires significant marketing and sales resources. This chart shows how the company is funding this important milestone.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio BioLineRx Ltd.
BioLineRx is a biopharmaceutical company focused on oncology. This chart shows its reliance on debt. For a company with a drug in late-stage clinical trials or already on the market, debt can be a tool for commercialization. This reflects the transition from the purely research phase to operational development.
Market segment debt to market segment book capitalization - General oncology therapy
BioLineRx is a clinical-stage biopharmaceutical company focused on oncology. This chart for the biotech sector illustrates how the industry as a whole raises capital to fund lengthy and expensive research. It provides context for assessing the financial viability of a company that does not yet have commercial products.
Debt to book value of all companies in the market
BioLineRx is a biopharmaceutical company developing drugs for oncology and rare diseases. This chart, showing the debt-to-book value ratio of the entire market, is important for assessing the investment climate. The market's willingness to finance companies with a diversified development pipeline determines BioLineRx's future.
P/E of the company, segment and market as a whole
P/E - BioLineRx Ltd.
BioLineRx is an Israeli biotech company with a late-stage drug for stem cell mobilization in cancer treatment. This chart reflects its proximity to commercialization. A rising indicator indicates investor confidence in the imminent approval and successful launch of its key drug, which will transform the company from a research-based company into a profitable one.
P/E of the market segment - General oncology therapy
BioLineRx Ltd. is a biotech company. This chart shows the average P/E ratio for the biotech sector. A company's P/E ratio is higher than average, suggesting that investors highly value its late-stage drug and its commercial prospects, considering it less risky than the average biotech.
P/E of the market as a whole
BioLineRx is an Israeli biotech company with one approved stem cell mobilization drug and several candidates in development. This chart illustrates the risk appetite in biotech. The company's valuation depends on the commercial success of its approved drug and the progress of its other assets in clinical trials, reflecting the balance between current revenue and future potential.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company BioLineRx Ltd.
BioLineRx is an Israeli late-stage biopharmaceutical company focused on oncology. The graph reflects revenue expectations, which are contingent on the prompt approval and commercial launch of its lead stem cell mobilization drug.
%20P%2FE%20BioLineRx%20Ltd.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-BioLineRx-Ltd.&v=1772546784908 "Chart of the company's future (projected) P/E BioLineRx Ltd.")
Future (projected) P/E of the market segment - General oncology therapy
BioLineRx is a late-stage biopharmaceutical company whose lead drug is designed to mobilize stem cells for cancer treatment. This chart shows how its future revenue expectations compare to the industry average, reflecting the market potential of its near-market-ready product.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772546784955 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
BioLineRx is an Israeli biotech company in late-stage development with a stem cell mobilization drug. Its valuation depends on the likelihood of approval and commercial launch of this product. This is a story close to its conclusion, less dependent on overall market sentiment, as seen here.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772546784998 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit BioLineRx Ltd.
BioLineRx Ltd. is a late-stage biopharmaceutical company focused on oncology. Its cash flows are generated by revenues from its approved drug and partnerships, as well as R&D expenses for other candidates. This chart shows the balance between commercialization and investments in the company's future oncology drug portfolio.
Profit of companies in the market segment - General oncology therapy
BioLineRx Ltd. is an Israeli late-stage biopharmaceutical company focused on oncology. This chart reflects the overall profitability of its sector. With a drug close to market, the company is on the cusp of commercialization. Its future sales could significantly impact overall profitability and become a key growth driver.
Overall market profit
BioLineRx is a late-stage biopharmaceutical company whose lead drug is designed to mobilize stem cells for cancer treatment. With its product approved, its success now hinges on commercialization and expanded indications. This chart shows common economic cycles as BioLineRx transitions from development to revenue generation.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company BioLineRx Ltd.
BioLineRx is a late-stage biopharmaceutical company focused on oncology. This chart reflects analysts' expectations for future earnings, based on the high potential of its lead stem cell mobilization drug, which has already been approved by the FDA. It demonstrates the market's confidence in the successful commercialization of the product.
%20profit%20of%20the%20company%20BioLineRx%20Ltd.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-BioLineRx-Ltd.&v=1772546785205 "Graph of future (projected) profit of the company BioLineRx Ltd.")
Future (predicted) profit of companies in the market segment - General oncology therapy
BioLineRx Ltd. is a late-stage biopharmaceutical company focused on oncology. This chart shows revenue projections for the oncology sector. It reflects expectations for the commercialization of drugs in late-stage clinical trials, a key milestone for biotech companies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772546785216 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
BioLineRx is a late-stage biopharmaceutical company. Their success depends on drug approval and commercialization. The projected market revenue impacts the investment climate and the company's valuation, which is important for funding marketing and sales launches, as well as for further research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772546785248 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - BioLineRx Ltd.
BioLineRx Ltd. is an Israeli biopharmaceutical company with an already approved stem cell mobilization drug. P/S is now a key metric for the company, reflecting the commercial success of its first product and the potential of its other developments.
P/S market segment - General oncology therapy
BioLineRx Ltd. is an Israeli late-stage biopharmaceutical company focused on oncology. Their lead drug is designed to mobilize stem cells during transplantation. This chart shows how the market views the commercial potential of their near-market-ready product and their pipeline of other developments.
P/S of the market as a whole
BioLineRx is an Israeli biotech company with a late-stage drug for stem cell mobilization. Revenue is dependent on the successful commercialization of this drug. This chart illustrates the average revenue estimate, which helps understand how the market values the company as it transitions from development to sales.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company BioLineRx Ltd.
BioLineRx is an Israeli biopharmaceutical company with a late-stage stem cell mobilization drug and other oncology developments. This chart reflects investor expectations for future revenue from its lead drug, which is close to commercialization, and the potential of the rest of its portfolio.
%20P%2FS%20BioLineRx%20Ltd.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-BioLineRx-Ltd.&v=1772546785331 "The graph of the company's future (projected) P/S BioLineRx Ltd.")
Future (projected) P/S of the market segment - General oncology therapy
BioLineRx Ltd. is a late-stage biopharmaceutical company focused on oncology. This chart shows how the market assesses the future commercial potential of its lead stem cell mobilization drug and other developments. It compares it to other companies in the general oncology sector, reflecting its advanced pipeline.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772546785394 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
BioLineRx is an Israeli biopharmaceutical company with an approved stem cell mobilization drug and other oncology developments. This chart reflects revenue expectations for the entire market, and BLRX exemplifies how the successful launch of a single drug can dramatically change the outlook for a biotech company.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772546785400 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales BioLineRx Ltd.
BioLineRx Ltd. is a biopharmaceutical company with a commercial product, APHEXDA®, designed to mobilize stem cells. Its revenue in this graph is generated from sales of this product and may also include milestone payments and royalties from partners in other programs under development.
Sales of companies in the market segment - General oncology therapy
BioLineRx is a late-stage biopharmaceutical company. This chart shows revenue from its first commercial product, APHEXDA. It allows investors to track the dynamics of initial sales, which is key to assessing the company's commercial potential.
Overall market sales
BioLineRx is an Israeli late-stage biopharmaceutical company with products in oncology and rare diseases. With a potential product on the cusp of commercialization, its success depends on regulatory approval and market launch. This general economic activity schedule does not affect these key events for the company.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company BioLineRx Ltd.
BioLineRx is a late-stage biopharmaceutical company with an approved stem cell mobilization drug and other oncology developments. Its revenue forecast depends on the commercial success of its core product. This chart shows analyst sales expectations for this important transplantation drug.
%20sales%20of%20the%20company%20BioLineRx%20Ltd.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-BioLineRx-Ltd.&v=1772546785518 "Schedule of future (projected) sales of the company BioLineRx Ltd.")
Future (projected) sales of companies in the market segment - General oncology therapy
BioLineRx Ltd. is a late-stage clinical development biopharmaceutical company focused on oncology. This chart displays projected revenue for the entire oncotherapy segment. It provides insight into how rapidly analysts expect this market to grow, which is critical to the future commercial success of BioLineRx's products.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772546785596 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
BioLineRx is an Israeli biopharmaceutical company developing drugs for the treatment of oncology and rare diseases. The company's success depends on regulatory approval and the commercialization of its products. This graph of general market expectations reflects the investment climate, which is important for funding marketing efforts and further clinical trials.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772546785614 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality BioLineRx Ltd.
BioLineRx is a late-stage biopharmaceutical company focused on oncology. This timeline depicts its path to commercialization. Future profitability depends on regulatory approval of its drugs and their successful launch, particularly its stem cell mobilization product.
Market segment marginality - General oncology therapy
BioLineRx Ltd. is a biopharmaceutical company developing treatments for oncology and rare diseases. Its lead drug, Motixafortide, is used to mobilize stem cells. This chart reflects the average profitability in the oncology sector. It allows one to assess the commercial success of Motixafortide and the potential of the company's other developments.
Market marginality as a whole
BioLineRx Ltd. is an Israeli late-stage biopharmaceutical company focused on oncology. This gross margin curve is irrelevant to BioLineRx's valuation, which is determined by the likelihood of approval of its lead drug candidate and its commercial potential.
Employees in the company, segment and market as a whole
Number of employees in the company BioLineRx Ltd.
BioLineRx is an Israeli biopharmaceutical company in late-stage development. Significant growth of its team, particularly in its commercial division, is a direct result of the FDA approval of its first drug. This chart clearly demonstrates the transition from an R&D company to a commercial organization.
Share of the company's employees BioLineRx Ltd. within the market segment - General oncology therapy
BioLineRx Ltd. is a late-stage biopharmaceutical company focused on oncology. This chart demonstrates its scientific potential. It reflects the percentage of oncologists, hematologists, and researchers working on the development and commercialization of innovative treatments, including a stem cell mobilization drug, that BioLineRx brings together under its umbrella.
Number of employees in the market segment - General oncology therapy
BioLineRx Ltd. is a biopharmaceutical company developing oncology drugs. This chart shows employment in the oncology therapeutics sector. The growing number of scientists and clinicians indicates a global increase in investment in the fight against cancer and the search for new drug combinations, creating an environment for BioLineRx's clinical trials.
Number of employees in the market as a whole
BioLineRx Ltd. is an Israeli clinical-stage biopharmaceutical company focused on oncology and rare diseases. Israel is a global hub for biotech innovation. This chart reflects overall employment, and companies like these make a significant contribution to the global pharmaceutical industry.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company BioLineRx Ltd. (BLRX)
BioLineRx is a biopharmaceutical company with several drugs in development. Its score on this chart represents the market's aggregate valuation of its research portfolio. It reflects the value investors place on the team's ability to manage multiple R&D projects and bring them to late stages.
%20of%20the%20company%20BioLineRx%20Ltd.%20(BLRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-BioLineRx-Ltd.-BLRX&v=1772546785983 "Chart of market capitalization per employee (in thousands of dollars) of the company BioLineRx Ltd. (BLRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
BioLineRx is a biopharmaceutical company with the already approved stem cell mobilization drug Aphexda. Its market value per employee reflects both current sales and the potential of other developments in its portfolio. This comparison with the sector helps assess how successfully the company has transitioned from R&D to commercialization.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772546786021 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
BioLineRx is a biopharmaceutical company with an approved stem cell mobilization drug and other programs in development. The availability of a commercial product changes the company's profile. This chart shows how the market values both current sales and the future potential of its research programs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772546786045 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company BioLineRx Ltd. (BLRX)
BioLineRx is a biotech company that has entered the commercial stage. Its lead drug (Aphexda) is approved for stem cell mobilization in oncology. This chart shows how successfully the sales team is bringing this niche, expensive drug to market, and how revenue is (or isn't) beginning to cover personnel costs.
%20Chart%20BioLineRx%20Ltd.%20(BLRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-BioLineRx-Ltd.-BLRX&v=1772546786158 "Company Profit Per Employee (in thousands of dollars) Chart BioLineRx Ltd. (BLRX)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
BioLineRx Ltd. is a late-stage biopharmaceutical company developing drugs for oncology and rare diseases. This chart reflects the potential of their pipeline. It demonstrates the significant returns that can accrue from successfully bringing a new drug to market, the culmination of years of research and investment by a small but effective team of scientists.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772546786313 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
BioLineRx Ltd. is an Israeli biopharmaceutical company with the approved drug Aphexda (for stem cell mobilization) and other oncology programs. This chart shows the transition from R&D expenses to revenue generation. It reflects how successfully their commercial team sells Aphexda, covering ongoing R&D costs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772546786424 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee BioLineRx Ltd. (BLRX)
BioLineRx is a biopharmaceutical company whose stem cell mobilization drug recently received approval. This schedule will reflect the start of commercialization. A sharp increase in revenue per employee is expected, demonstrating the financial success of years of research and development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-BioLineRx-Ltd.-BLRX&v=1772546786512 "Sales chart per company employee BioLineRx Ltd. (BLRX)")
Sales per employee in the market segment - General oncology therapy
BioLineRx (BLRX) is an Israeli biopharmaceutical company whose key drug (Aphexda/Motixafortide) is approved for stem cell mobilization during transplantation. This chart shows the average revenue per employee in the pharmaceutical segment. Comparing BLRX to this benchmark demonstrates how productive their team is in commercializing their approved drug.
Sales per employee for the market as a whole
BioLineRx (BLRX) is a biotech company that recently had a drug (Aphexda) approved for stem cell transplantation. Until recently, its stock price was flat. Investors are now expecting a sharp rise, which will indicate how successfully the company has commercialized its first drug.
Short shares by company, segment and market as a whole
Shares shorted by company BioLineRx Ltd. (BLRX)
BioLineRx is an Israeli biotech company that recently received approval for its stem cell mobilization drug (Aphexda). This chart shows the odds of commercial failure. Bears believe that despite approval, the drug will not be used by doctors, and its sales will not cover development costs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-BioLineRx-Ltd.-BLRX&v=1772546786650 "Short Shares Chart for the Company BioLineRx Ltd. (BLRX)")
Shares shorted by market segment - General oncology therapy
BioLineRx (BLRX) is an Israeli biotech with an already approved drug (Aphexda) for stem cell mobilization in cancer treatment. This chart highlights the pessimism in the sector. The growing short position across the industry is a bet that BLRX will fail commercially. Investors doubt that Aphexda will be able to capture market share from existing treatment standards.
Shares shorted by the overall market
BioLineRx is a biotech that has secured approval for a drug (Aphexda) for stem cell transplants. This chart illustrates the overall market pessimism. Even with an approved product, investors may panic and have doubts. They fear that commercialization will be slow, competition will be intense, and the company will fail to turn a profit.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator BioLineRx Ltd. (BLRX)
This chart shows the market's reaction to BioLineRx's progress. The key event is the FDA approval of their drug Aphexda for stem cell mobilization in myeloma. "Overbought" levels (above 70) arise from news of a successful commercial launch or progress in other programs (pancreatic cancer). A slow sales start or clinical failures lead to "oversold" levels.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-BioLineRx-Ltd.-BLRX&v=1772546786966 "RSI 14 indicator chart for the company's stock BioLineRx Ltd. (BLRX)")
RSI 14 Market Segment - General oncology therapy
BioLineRx (BLRX) is an Israeli biotech company and a cancer hunter. Their specialty is a drug (Motixafortide) for stem cell mobilization (for myeloma) and the treatment of pancreatic cancer. The "General Oncology Therapy" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It helps us understand: is BLRX's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
BioLineRx (BLRX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BLRX (BioLineRx Ltd.)
BioLineRx (BLRX) is an Israeli company whose flagship drug, Aphexda, is approved for stem cell mobilization in the treatment of myeloma. This chart shows the average target price. It reflects analyst expectations for the commercial success of this drug's launch in the US and Europe.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BLRX-BioLineRx-Ltd.&v=1772546787108 "A chart showing analyst consensus forecasts for the expected stock price. BLRX (BioLineRx Ltd.)")
The difference between the consensus estimate and the actual stock price BLRX (BioLineRx Ltd.)
BioLineRx is an Israeli biotech company whose flagship drug, APHEXDA, is approved for stem cell mobilization during transplantation. This chart shows how much the current share price differs from the "fair" value predicted by analysts. It reflects their confidence in the drug's commercial launch.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BLRX-BioLineRx-Ltd.&v=1772546787131 "A chart showing the difference between the consensus forecast and the actual stock price. BLRX (BioLineRx Ltd.)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
BioLineRx is an Israeli biotech that recently received FDA approval for its lead drug (Aphexda) for stem cell mobilization in cancer patients. This chart reflects analysts' overall expectations across the oncology sector, demonstrating whether experts believe new drugs in this field will be commercially successful.
Analysts' consensus forecast for the overall market share price
BioLineRx is an Israeli biotech company focused on developing drugs for oncology and hematology (specifically, stem cell mobilization). This chart shows the overall market "risk appetite." For BioLineRx, a clinical-stage company, overall market optimism (an upward trend in the chart) is critical for attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index BioLineRx Ltd.
BioLineRx is an Israeli biotech company that just crossed the finish line. After years of R&D, they received FDA approval for their first product (Aphexda), a stem cell mobilization drug for the treatment of blood cancers. This graph is a summary of their new life, reflecting their (slow) commercial launch and their ability to monetize their R&D.
AKIMA Market Segment Index - General oncology therapy
BioLineRx (BLRX) is an Israeli biopharmaceutical company with the approved drug APHEXDA (Motixafortide), which is used to mobilize stem cells in the treatment of multiple myeloma. The chart shows the average index for the segment, helping investors assess how the commercialization of this drug compares to the oncology sector average.
The AKIM Index for the overall market
BioLineRx is an Israeli biopharmaceutical company commercializing a drug (Aphexda) for stem cell mobilization during transplantation. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which has transitioned to sales, compares to overall economic trends.
